Is Higher Dose of Inhaled Treprostinil Truly Superior to Lower Dose of Inhaled Treprostinil in Patients With Pulmonary Hypertension Associated With Interstitial Lung Diseases ?
ContributorsGenecand, Léon; Lador, Frédéric; Montani, David; Perneger, Thomas
Published inChest, vol. 165, no. 5, e161
Publication date2024-05
First online date2024-05
Abstract
Keywords
- Humans
- Epoprostenol / analogs & derivatives
- Epoprostenol / administration & dosage
- Lung Diseases, Interstitial / drug therapy
- Lung Diseases, Interstitial / complications
- Hypertension, Pulmonary / drug therapy
- Administration, Inhalation
- Antihypertensive Agents / administration & dosage
- Antihypertensive Agents / therapeutic use
- Dose-Response Relationship, Drug
Affiliation entities
Citation (ISO format)
GENECAND, Léon et al. Is Higher Dose of Inhaled Treprostinil Truly Superior to Lower Dose of Inhaled Treprostinil in Patients With Pulmonary Hypertension Associated With Interstitial Lung Diseases ? In: Chest, 2024, vol. 165, n° 5, p. e161. doi: 10.1016/j.chest.2023.12.032
Main files (1)
Article (Published version)
Identifiers
- PID : unige:190458
- DOI : 10.1016/j.chest.2023.12.032
- PMID : 38724160
Additional URL for this publicationhttps://www.sciencedirect.com/science/article/pii/S0012369224000084
Journal ISSN0012-3692
